David Novak

Stock Analyst at Raymond James

(0.73)
# 3,905
Out of 4,915 analysts
9
Total ratings
44.44%
Success rate
-11.22%
Average return
Main Sectors:
Top Industries:

Stocks Rated by David Novak

Zymeworks
Dec 10, 2021
Downgrades: Outperform
Price Target: $74
Current: $12.57
Upside: +488.70%
Leap Therapeutics
Mar 2, 2021
Maintains: Outperform
Price Target: $25$35
Current: $0.31
Upside: +11,190.32%
Crescent Biopharma
Feb 4, 2021
Maintains: Outperform
Price Target: $300$270
Current: $12.42
Upside: +2,073.91%